Tango Therapeutics (TNGX) revenue and earnings history
Tango Therapeutics reported revenue of $62.4M for fiscal 2025 (year ended Dec 31, 2025), +48.3% on the year before, and net income of −$102M.
Over 5 years, from fiscal 2020 to fiscal 2025, revenue grew at a compound rate of +52.1% a year.
Revenue and net income, 6 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $62.4M+48.3% | −$111M | −$102M | −$139M | $1.05M | −$140M | $26.4M | — | — | $112M | — | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Tango Therapeutics (TNGX) on OQRO.
Common questions
What was Tango Therapeutics's revenue in fiscal 2025?
$62.4M for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 5, 2026. That is +48.3% on fiscal 2024 ($42.1M).
How fast has Tango Therapeutics's revenue grown?
From $7.66M in fiscal 2020 to $62.4M in fiscal 2025: a compound annual growth rate of +52.1% over 5 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Tango Therapeutics been profitable?
Where these figures come from
The SEC’s companyfacts data: every figure Tango Therapeutics tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
